Drug Trial Radar · NCT05135559
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
Mar 24, 2022
Primary completion
Apr 21, 2026
Study completion Nov 2, 2029
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Conditions
- Haemophilia A and B With and Without Inhibitors
Interventions
ConcizumabDrug
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodesTime frame: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
- For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodesTime frame: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Locations
91 sites in 24 countries. Site status is shown where the registry gives one.
Rady Childrens Hosp San Diego
San Diego, California
University of Colorado Hospital
Aurora, Colorado
Arnold Palmer Children's Hospital
Orlando, Florida
Nemours Child Orlando Hem/Onc.
Orlando, Florida
Augusta Univ/Childrens Hosp-GA
Augusta, Georgia
Memorial Health University Medical Center
Savannah, Georgia
Childrens Hospital of Chicago
Chicago, Illinois
Indiana Hemophilia-Thromb Ctr
Indianapolis, Indiana
Children's Hosp-New Orleans
New Orleans, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana
The Children's Mercy Hospital
Kansas City, Missouri
Children's Nebraska
Omaha, Nebraska
ECU Sickle Cell Comp Clinic
Greenville, North Carolina
Nationwide Children's Hospital
Columbus, Ohio
St Christopher Hosp for Child
Philadelphia, Pennsylvania
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee
Cook Children's Hospital-Hematology-Oncology
Fort Worth, Texas
Texas Children's Hospital_Houston
Houston, Texas
Pediatrics Hematology/Oncology Clinic Battle Building
Charlottesville, Virginia
Haematology and Blood Bank Department
Algiers, Algeria
CHU Constantine BEN BADIS/ Hematology department
Constantine, Algeria
University Clinical Center of Republic Srpska (545)
Banja Luka, Bosnia and Herzegovina
University Clinical Centre Tuzla
Tuzla, Bosnia and Herzegovina
UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
Plovdiv, Bulgaria
UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
Sofia, Bulgaria
UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
Varna, Bulgaria
BC Children's Hospital
Vancouver, British Columbia, Canada
McMaster Children's Hospital
Hamilton, Ontario, Canada
Tallinn Children's Hospital
Tallinn, Estonia
Centre Hospitalier Metropole Savoie
Chambéry, France
Ap-Hp-Hopital de Bicetre-1
Le Kremlin-Bicêtre, France
AP-HP-HOPITAL NECKER_Service d'hématologie
Paris, France
Aghia Sophia Childrens' Hospital
Athens, Greece
'Ippokrateio' General Hospital of Thessaloniki
Thessaloniki, Greece
'Ippokrateio' General Hospital of Thessaloniki
Thessaloniki, Greece
Guwahati Medical College
Guwahati, Assam, India
Nirmal Hospital Pvt. Ltd.
Surat, Gujarat, India
SSSH_Dept. of Clinical Haematology & Haemato Oncology
Kolhāpur, Maharashtra, India
Seth GS Medical College & KEM Hospital
Mumbai, Maharashtra, India
K.J Somaiya Hospital and Research Centre
Mumbai, Maharashtra, India
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.